Bruises Clinical Trial
Official title:
THE PRISM Study-Low-Molecular-Weight Heparin Versus Unfractionated Heparin for Perioperative Bridging Anticoagulation: the Patient Preference for Self-Injection Study and Related Measurements
The purpose of this study is to determine which short-acting blood thinner (low-molecular-weight heparin [Enoxaparin] or unfractionated heparin) is associated with less discomfort and bruising when given as a subcutaneous (under the skin) injection before and after a planned surgery or procedure in patients who temporarily stop warfarin.
Increasing Patient Comfort and Compliance: The Bridging Anticoagulation Clinic strives to
provide the highest quality of care to patients who require temporary interruption of
warfarin therapy. An important component of optimizing patient care is minimizing patient
discomfort with perioperative administration of short-acting anticoagulants (LWMH or UFH)
used for bridging therapy, which, in turn, may optimize patient compliance with this
treatment. This issue is especially relevant for patients who are receiving out-of-hospital
treatment with LMWH or UFH because about 85% of such patients will be taught to
self-administer this medication. This study seeks to determine if there is less discomfort
and bruising associated with self-injection of LMWH than with UFH.
Minimizing Injection Site Bruising: No studies, to our knowledge, have assessed the
characteristics or clinical importance of bruising in patients receiving subcutaneous LMWH
or UFH. Thus, there is no evidence to support any association between bruising and
discomfort. To bridge this gap in knowledge, we will document each injection site during the
course of the study and measure the amount of bruising observed using a standardized
photographic methodology. Injection site bruising has the potential to cause medical
problems if an injection site hematoma develops, which can become infected or can cause
long-term discomfort.
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04908748 -
Efficacy and Safety of Esflurbiprofen Hydrogel Patch in the Treatment of Local Acute Pain
|
Phase 2 |